Tuberculosis patients will soon be able to receive personalized treatment depending upon the version of their `Goldilocks` gene (LTA4H).
Scientists from the Oxford University, King`s College London, Vietnam and the US have found that people generate varying immune reactions to TB according to what version of the LTA4H gene they have.
Thus an individual`s genetic profile can determine which drug will work best for them. The researchers also showed that steroids used as part of the standard treatment for the most severe form of tuberculosis and TB meningitis, benefit only some patients.
The results of the study are published in the journal Cell.